We’re now in the 6th year of the COVID-19 pandemic. ➡️ What began as a respiratory illness has evolved into something deeper — a prolonged impact on the immune system. This is what some call the ‘Leonardi Effect’, after immunologist @fitterhappierAJ ➡️ He warned early that SARS-CoV-2 could hyperactivate T-cells — the cells that drive our immune defense. This overdrive may: • Cause tissue damage • Exhaust T-cells • Reduce immune memory • Leave us less protected against future infections. 1/

IL-6 and IL-8 elevations after co-administration of COVID-19 and influenza vaccines are associated with lower anti-spike IgG titers at three and six months post-vaccination 🔥For those still in doubt: don’t take both vaccines together( →4-6 weeks). ➡️"Coordinated activation of cytokines 5 days after dual COVID-19 and Flu vaccination." ➡️"The IL-6 and IL-8 increase negatively correlated with anti-S IgG at 3- and 6-months." ➡️Subsequently the "Inflammatory cytokine response may limit persistence of vaccine-induced antibody response." ‼️So, co-administration may impair long-term COVID-19 antibody persistence due to early inflammatory cytokines (e.g., IL-6, IL-8) negatively correlating with mid-term IgG titers. sciencedirect.com/science/ar…

Who could have predicted? 🥴 2020: “A high proportion of children with SARS-CoV-2 infection met clinical & diagnostic criteria for thrombotic microangiopathy. They also found the elevated biomarkers in children with asymptomatic/mild infections.” chop.edu/news/chop-researche…

He just wanted to take his dog for a walk in the town he's lived all his life.

A single dose of a new cancer drug made a brain tumor almost disappear – in just five days. Doctors at Massachusetts General Hospital reported “dramatic and rapid” tumor regression in the first patients treated with a next-generation form of CAR T-cell therapy for glioblastoma, one of the most aggressive brain cancers known. The therapy, called CARv3-TEAM-E, was developed to overcome a major hurdle in treating solid tumors: their ability to hide from the immune system. The personalized treatment reprograms a patient’s immune cells to attack the tumor, and in one extraordinary case, nearly eliminated the cancer within just five days. This novel therapy is designed to target multiple features of the tumor at once, a strategy that may help overcome the common challenge of treatment resistance in solid tumors like glioblastoma. Although the tumors eventually returned, the early outcomes were described as unprecedented. One patient saw a 60% reduction in tumor size that lasted for half a year—an impressive result in a cancer known for its aggressiveness. The trial’s success marks a major step forward for immunotherapy in brain cancer and raises new hopes for long-term control or even a cure. Researchers are now working to refine the treatment and extend its effects, with the ultimate goal of turning a once-terminal diagnosis into a survivable condition.